Details of Drug-Drug Interaction
| Drug General Information (ID: DDI9EJG3C0) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Drug Name | Enoxacin | Drug Info | Glipizide | Drug Info | |||||
| Drug Type | Small molecule | Small molecule | |||||||
| Therapeutic Class | Antiinfective Agents | Antidiabetic Agents | |||||||
| Structure | |||||||||
| Mechanism of Enoxacin-Glipizide Interaction (Severity Level: Major) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Increased risk of hypoglycemia Click to Show/Hide Mechanism Graph | |||||||||
 |
|||||||||
| Drug Name | Enoxacin | Glipizide | |||||||
| Mechanism 1 | Hypoglycemic effects | Antidiabetic agent | |||||||
| Key Mechanism Factor 1 | |||||||||
| Factor Name | Hypoglycemia | ||||||||
| Factor Description | Hypoglycemia is a condition in which your blood sugar (glucose) level is below the standard range. It causes irregular or rapid heartbeat, pale skin, numbness of the lips, tongue or cheeks, and sweating. | ||||||||
| Mechanism Description |
|
||||||||
| Antagonize the effect of antidiabetic agents Click to Show/Hide Mechanism Graph | |||||||||
 |
|||||||||
| Drug Name | Enoxacin | Glipizide | |||||||
| Mechanism 2 | Hyperglycemia | Antidiabetic agent | |||||||
| Key Mechanism Factor 2 | |||||||||
| Factor Name | Antidiabetic agents | ||||||||
| Factor Description | The hypoglycemic effect of antidiabetes may be reduced, leading to higher blood glucose, increased blood glucose fluctuations, and the possibility of hyperglycemic complications | ||||||||
| Mechanism Description |
|
||||||||
| Mechanism 3 | Hyperglycemic effects | Antidiabetic agent | |||||||
| Key Mechanism Factor 3 | |||||||||
| Factor Name | Antidiabetic agents | ||||||||
| Factor Description | The hypoglycemic effect of antidiabetes may be reduced, leading to higher blood glucose, increased blood glucose fluctuations, and the possibility of hyperglycemic complications | ||||||||
| Mechanism Description |
|
||||||||
| Recommended Action | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Management | Blood glucose should be closely monitored whenever quinolones are prescribed to diabetic patients, especially if they are elderly, have renal impairment, or are severely ill. Due to the risk of profound and potentially life-threatening hypoglycemia, particular caution is advised during concomitant use of insulin and insulin secretagogues (e.g., sulfonylureas, meglitinides). Patients should also be apprised of the increased risk of hypoglycemia and be alert to potential signs and symptoms such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia. If hypoglycemia occurs, patients should initiate appropriate remedial therapy immediately, discontinue the quinolone, and contact their physician. alternative antibiotics may need to be considered. | ||||||||